SHANGHAI, March 2, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the Center for Drug Evaluation (CDE) of China's National...
Read More Details
Finally We wish PressBee provided you with enough information of ( CARsgen's Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA )
Also on site :
- NBC Catches Wrath of Fans After Canceling 5 Beloved Shows
- PHOTO COLLECTION: Romania Election Pro-EU Rally
- Michele Val Jean Reunites With ‘Beyond The Gates’ Cast and Crew in Atlanta